Application of chondramus polysaccharide in intervention of lung cancer

Abstract

The application discloses application of chondroitin polysaccharide in intervention of lung cancer and belongs to the technical field of medicine. The chondroitin polysaccharide composition is prepared by compounding chondroitin polysaccharide, extract of eupatorium fortunei, extract of eucommia ulmoides leaf and extract of allium bakeri, the composition has good tumor inhibition effect and the effect is better than that of only using chondroitin polysaccharide, and the application has potential medical application prospect and provides strong support for development of a new drug.

Description

TECHNICAL FIELD

[0001] The present application relates to the application of chufa polysaccharide in the intervention of lung cancer, and belongs to the technical field of medicine. BACKGROUND

[0002] Lung cancer, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), is one of the most common malignant tumors, and its morbidity and mortality rank in the forefront among malignant tumors, seriously endangering human health and quality of life. Due to its very complex biological characteristics, the pathogenesis of lung cancer has not been fully revealed. The clinical treatment methods mainly include surgical treatment, chemotherapy, radiotherapy, etc., but these methods can cause serious damage to other organs of the human body and easily lead to the occurrence of other diseases, therefore, it is of great significance to develop new methods for preventing and intervening lung cancer.

[0003] Chufa is the dried root of the plant Cyathula officinalis Klotz, also known as Baibei and Niuji, etc., which is collected as a commonly used traditional Chinese medicine in the Pharmacopoeia of the People's Republic of China. Chufa polysaccharide is a water-soluble polysaccharide compound obtained by separation, extraction and purification from the roots of chufa, which has anti-tumor, antioxidant, anti-viral, immune regulation and other pharmacological effects. Patent CN111450110A discloses the effect of chufa polysaccharide in preventing metastasis of non-small cell lung cancer; patent CN105859904A discloses the extract of chufa stems and / or leaves and / or roots and its extraction method, which has the functions of inhibiting cancer and enhancing immunity. The literature "Research Progress of Chufa Polysaccharide in Anti-tumor" discloses a series of potential mechanisms of chufa polysaccharide in anti-tumor.

[0004] However, the existing technology has general inhibitory effect of chufa polysaccharide on tumors, and is limited to the exploration of the function of chufa polysaccharide, ignoring the potential synergistic effect between different medicinal materials. At present, there is no report on the synergistic intervention of chufa polysaccharide and other medicinal materials on cancer. Therefore, improving the anti-tumor effect of chufa polysaccharide by other medicinal materials is a potential method to improve chufa polysaccharide, which has a positive promoting effect on the functional research of chufa polysaccharide. SUMMARY

[0005] To solve the above problems, the present application prepares a chufa polysaccharide composition by compounding chufa polysaccharide with extract of aletris farinosa, extract of eucommia ulmoides leaf and extract of allium macrostemon bunge, which has good tumor inhibitory effect and is better than using chufa polysaccharide alone. The present application has potential medical application prospects and provides strong support for the development of new drugs.

[0006] The first object of the present application is to provide a chufa polysaccharide composition, which comprises chufa polysaccharide, extract of aletris farinosa, extract of eucommia ulmoides leaf and extract of allium macrostemon bunge.

[0007] In an embodiment, the chondroitin polysaccharide composition comprises, by mass fraction, 30-80 parts of chondroitin polysaccharide, 20-30 parts of water extract of aleuritopteris chinensis, 10-20 parts of eucommia leaf extract, and 5-15 parts of allium macrostemon Bunge extract.

[0008] A second object of the present application is to provide use of the chondroitin polysaccharide composition in the preparation of a drug for intervening lung cancer, characterized in that the chondroitin polysaccharide composition comprises chondroitin polysaccharide, aleuritopteris chinensis extract, eucommia leaf extract, and allium macrostemon Bunge extract.

[0009] In an embodiment, the chondroitin polysaccharide composition comprises, by mass fraction, 30-80 parts of chondroitin polysaccharide, 20-30 parts of water extract of aleuritopteris chinensis, 10-20 parts of eucommia leaf extract, and 5-15 parts of allium macrostemon Bunge extract.

[0010] In an embodiment, the drug comprises a pharmaceutically acceptable excipient.

[0011] In an embodiment, the excipient comprises one or more of lactose, maltose, microcrystalline cellulose, carboxymethyl cellulose, polyvinyl pyrrolidone, hydroxypropyl methyl cellulose, polymethyl methacrylate, starch, sucrose, glucose, aspartame, water, ethanol, glycerol, benzoic acid, formic acid, and sodium benzoate.

[0012] In an embodiment, the drug is in any dosage form that is pharmaceutically acceptable.

[0013] In an embodiment, the dosage form comprises tablets, capsules, liquid preparations, injections, granules, tinctures, suppositories, patches, and inhalation preparations.

[0014] In an embodiment, the method for preparing chondroitin polysaccharide comprises:

[0015] The chondroitin is sliced and soaked in water for 48-60 hours at a solid-liquid ratio of 1g:5-8mL, the residue is filtered out, acetone is added, the precipitate is allowed to settle, the precipitate is redissolved in water, dialyzed for 60-72 hours, and freeze-dried to obtain crude chondroitin polysaccharide; the crude chondroitin polysaccharide is dissolved in water, 6 times the volume of anhydrous ethanol is added, and the precipitate is separated to obtain refined chondroitin polysaccharide.

[0016] In an embodiment, the method for preparing the aleuritopteris chinensis extract, eucommia leaf extract, and allium macrostemon Bunge extract comprises: using a pulverizer to pulverize the three kinds of medicinal materials, namely aleuritopteris chinensis, eucommia leaf, and allium macrostemon Bunge, respectively, adding water and heating to extract, filtering after extraction to obtain supernatant, and drying the supernatant to obtain the aleuritopteris chinensis extract, eucommia leaf extract, and allium macrostemon Bunge extract, respectively.

[0017] In one embodiment, the preparation method of the extract of the Herbae Humuli, the leaves of Eucommia ulmoides, and the Bulbus Allii Macrostemonis is as follows: the Herbae Humuli, the leaves of Eucommia ulmoides, and the Bulbus Allii Macrostemonis are added to water in a mass-volume ratio of 1: (5-15), heated to 95-100 DEG C to reflux extract for 1-3 hours, filtered, and the first supernatant is taken; the residue is extracted again according to the above process to obtain the second supernatant; then the second and the second supernatants are combined, concentrated, and freeze-dried into powder to obtain the extract of the Herbae Humuli, the leaves of Eucommia ulmoides, and the Bulbus Allii Macrostemonis.

[0018] A third object of the present application is to provide a method for improving the anti-tumor effect of the polysaccharide of Radix Achyranthis Bidentatae, characterized in that the polysaccharide of Radix Achyranthis Bidentatae is compounded with the extract of Herbae Humuli, the extract of the leaves of Eucommia ulmoides, and the extract of the Bulbus Allii Macrostemonis to obtain a polysaccharide of Radix Achyranthis Bidentatae composition; wherein the polysaccharide of Radix Achyranthis Bidentatae composition comprises, in mass parts, 30-80 parts of the polysaccharide of Radix Achyranthis Bidentatae, 20-30 parts of the water extract of Herbae Humuli, 10-20 parts of the extract of the leaves of Eucommia ulmoides, and 5-15 parts of the extract of the Bulbus Allii Macrostemonis.

[0019] Beneficial effects

[0020] The present application prepares the polysaccharide of Radix Achyranthis Bidentatae composition by compounding the polysaccharide of Radix Achyranthis Bidentatae with the extract of Herbae Humuli, the extract of the leaves of Eucommia ulmoides, and the extract of the Bulbus Allii Macrostemonis, and the composition has better tumor inhibition and immune regulation effects, which are superior to those of the polysaccharide of Radix Achyranthis Bidentatae alone.

[0021] Specifically, the polysaccharide of Radix Achyranthis Bidentatae composition has the following effects:

[0022] (1) The anti-tumor effect of the polysaccharide of Radix Achyranthis Bidentatae composition reaches 64%, which is increased by 33.3% compared with the polysaccharide of Radix Achyranthis Bidentatae;

[0023] (2) The polysaccharide of Radix Achyranthis Bidentatae composition significantly restores the immune organ index to the normal level;

[0024] (3) The polysaccharide of Radix Achyranthis Bidentatae composition reduces the expression of TNF-α, IL-1β, and IL-6 by 21.7%, 28.4%, and 26.1%, respectively;

[0025] (4) The polysaccharide of Radix Achyranthis Bidentatae composition reduces the expression of VEGF, TGF-β, and PDGF-BB by 19.4%, 30.5%, and 21.4%, respectively. BRIEF DESCRIPTION OF DRAWINGS

[0026] Figure 1 The pathological changes of the tumor tissue of the mouse (HE staining, 200 times magnification) are shown in Figure 1;

[0027] Figure 2 The immunohistochemical analysis of Ki67 of the tumor tissue of the mouse is shown in Figure 3. DETAILED DESCRIPTION

[0028] The following describes preferred embodiments of the present application, and it should be understood that the embodiments are for better explaining the present application and are not intended to limit the present application.

[0029] Materials:

[0030] 1. C57BL / 6 mice (male, 20±2 g, SPF) were purchased from Jiangsu Huacheng Xinnuo Pharmaceutical Technology Co., Ltd. All animal experiments were approved by the Animal Ethics Committee of Jiangnan University, and all experimental procedures were strictly in accordance with the National Guide to Laboratory Animal Welfare.

[0031] 2. Lewis lung cancer cells were purchased from the Chinese Academy of Sciences Cell Bank.

[0032] Detection method:

[0033] 1. Tumor inhibition rate % = (1 - tumor weight in the administration group / tumor weight in the model group) * 100%.

[0034] 2. Immune organ index determination: After the mice were sacrificed, the immune organs of the spleen and thymus were removed, weighed, and the spleen index and thymus index were calculated;

[0035] Spleen index = Spleen weight / Mouse live weight;

[0036] Thymus index = Thymus weight / Mouse live weight.

[0037] 3. Serum cytokine detection

[0038] The levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), transforming growth factor-β (TGF-β), and platelet-derived growth factor-BB (PDGF-BB) in the mouse serum were detected using an enzyme-linked immunosorbent assay (ELISA) kit (Shanghai Fankuo Biological Technology Co., Ltd., China).

[0039] 4. Tumor tissue section and immunohistochemical staining method

[0040] The tumor tissue was fixed in 4% paraformaldehyde and then embedded in paraffin, and cut into 4 μm thick sections. Then, the sections were stained with hematoxylin and eosin (H&E).

[0041] For immunohistochemistry, the tumor sections were first subjected to antigen retrieval and serum blocking treatment for 30 minutes, and then incubated with the primary antibody. Then, the mouse / rabbit secondary antibody was applied on the sections for 30 minutes. Subsequently, diaminobenzidine (DAB) staining was performed, followed by hematoxylin counterstaining and differentiation with 1% hydrochloric acid ethanol. Finally, gradient ethanol dehydration, xylene clarification, and neutral gum sealing were performed. Finally, the images were collected and analyzed using a digital slide scanning system.

[0042] Example 1: Preparation of Achyranthes bidentata polysaccharide

[0043] Preparation of Achyranthes bidentata polysaccharide:

[0044] The preparation method of Achyranthes bidentata polysaccharide (AP) can refer to patent CN1014322B.

[0045] Take sliced Achyranthes bidentata crude drug, add 5 times the weight of the medicinal material distilled water, soak for 48 h, then centrifuge at room temperature to remove the insoluble matter to obtain supernatant (I). Add acetone to the supernatant (I), centrifuge to obtain supernatant (II). Add acetone again to the supernatant (II) to produce white precipitate. Let the precipitate settle naturally, place the supernatant, and take out the precipitate. Dissolve the precipitate with an appropriate amount of distilled water, dialysis, centrifugal removal of insoluble matter, freeze-drying to obtain crude Achyranthes bidentata polysaccharide. Dissolve the crude Achyranthes bidentata polysaccharide with water, add 6 times the volume of anhydrous ethanol to produce white precipitate. Centrifuge to take out the precipitate, dissolve it with water, dialysis, and freeze-drying to obtain refined Achyranthes bidentata polysaccharide.

[0046] Example 2: Preparation of Achyranthes bidentata polysaccharide composition

[0047] Take the Achyranthes bidentata polysaccharide prepared in Example 1 to prepare Achyranthes bidentata polysaccharide composition.

[0048] 1. Preparation of medicinal material composition

[0049] Use Herba Equiseti, Eucommia ulmoides leaf, and Allium macrostemon Bunge to prepare traditional Chinese medicinal material composition, and the steps are as follows:

[0050] Grind the plant medicinal materials (Herba Equiseti / Eucommia ulmoides leaf / Allium macrostemon Bunge) with a grinder, then add 8 times the weight of the medicinal material of pure water, heat to 100℃ and reflux extract for 2h, filter, and take the supernatant. The dregs are extracted again according to the above process to obtain the supernatant. Combine the two supernatants to obtain Herba Equiseti extract supernatant, Eucommia ulmoides leaf extract supernatant, and Allium macrostemon Bunge extract supernatant, respectively. Concentrate and freeze-dry to obtain Herba Equiseti extract, Eucommia ulmoides leaf extract, and Allium macrostemon Bunge extract.

[0051] Take 20 parts of Herba Equiseti water extract, 15 parts of Eucommia ulmoides leaf extract, and 5 parts of Allium macrostemon Bunge extract by mass fraction, mix them evenly to obtain the medicinal material composition.

[0052] 2. Preparation of Achyranthes bidentata polysaccharide composition

[0053] The Achyranthes bidentata polysaccharide composition is composed of Achyranthes bidentata polysaccharide, Herba Equiseti extract, Eucommia ulmoides leaf extract, and Allium macrostemon Bunge extract.

[0054] Take the Herba Equiseti extract, Eucommia ulmoides leaf extract, and Allium macrostemon Bunge extract prepared in 1, and configure to obtain Achyranthes bidentata polysaccharide composition by mass fraction, wherein Achyranthes bidentata polysaccharide is 60 parts, Herba Equiseti water extract is 20 parts, Eucommia ulmoides leaf extract is 15 parts, and Allium macrostemon Bunge extract is 5 parts. Mix them evenly to obtain Achyranthes bidentata polysaccharide composition.

[0055] Example 3: Application of Radix Achyranthis Bidentatae Polysaccharide and Radix Achyranthis Bidentatae Polysaccharide Composition in Inhibiting Lung Cancer

[0056] The Radix Achyranthis Bidentatae Polysaccharide, medicinal material composition and Radix Achyranthis Bidentatae Polysaccharide composition prepared in Example 1 and Example 2 were used to prepare Radix Achyranthis Bidentatae Polysaccharide, medicinal material composition and Radix Achyranthis Bidentatae Polysaccharide composition solutions with normal saline, and the inhibitory effect on lung cancer was detected.

[0057] 1. Construction of lung cancer mice

[0058] The mice were raised under standard conditions of temperature 22±2℃, relative humidity 55±15%, 12-hour light / dark cycle, free access to food and water. After 1 week of adaptation, the mice were randomly divided into 5 groups, 8 mice in each group, namely the control group (given the same volume of normal saline), the model group (given the same volume of normal saline), the Radix Achyranthis Bidentatae Polysaccharide group (the Radix Achyranthis Bidentatae Polysaccharide dosage was 150 mg / kg of mouse body weight / d), the medicinal material composition group (the medicinal material composition dosage was 150 mg / kg of mouse body weight / d), and the Radix Achyranthis Bidentatae Polysaccharide composition group (the Radix Achyranthis Bidentatae Polysaccharide composition dosage was 150 mg / kg of mouse body weight / d).

[0059] In order to establish a lung cancer mouse model, the Lewis lung cancer cells (LLC) were cultured to the logarithmic growth phase, and phosphate buffered saline (PBS) was used to prepare a 2×10 6 / mL cell suspension. Except for the control group, 0.2 mL was subcutaneously injected into the right axillary fossa of each mouse. In order to evaluate the intervention effect of Radix Achyranthis Bidentatae Polysaccharide on tumors, continuous gavage was performed for 21 days, and the living conditions and tumor size of the animals were strictly monitored during the administration period. On the last day, the eyeball blood was collected, the blood was collected, and the mouse tumor, spleen and thymus were removed for further study.

[0060] 2. Inhibition of tumor proliferation by Radix Achyranthis Bidentatae Polysaccharide and Radix Achyranthis Bidentatae Polysaccharide composition

[0061] The tumor inhibition rate is the most basic and important indicator for measuring whether a drug has anti-tumor effectiveness, and is the main basis for screening anti-tumor drugs. In this study, after the mice were inoculated with tumor cells, the axillary tumor mass gradually grew, and the mice in the remaining groups showed different degrees of movement retardation, dull hair, and relatively reduced food intake, except for the blank group.

[0062] Table 1 Effect of Radix Achyranthis Bidentatae Polysaccharide and its composition on lung cancer tumors in mice

[0063] Group Dose Tumor inhibition rate (%) Model group Saline - Radix Achyranthis Bidentatae polysaccharide 150 mg / kg / d 48％ Medicinal material composition 150 mg / kg / d 30％ Radix Achyranthis Bidentatae polysaccharide composition 150 mg / kg / d 64％

[0064] The tumor inhibition rate is the most basic and important indicator for measuring whether a drug has anti-tumor effectiveness, and is the main basis for screening anti-tumor drugs. In this study, after the mice were inoculated with tumor cells, the axillary tumor mass gradually grew, and the mice in the remaining groups showed different degrees of movement retardation, dull hair, and relatively reduced food intake, except for the blank group.

[0065] The tumor section, immunohistochemical results are shown in Figure 1 、 Figure 2 The He staining results show that the tumor cells in the model group are complete in shape, closely arranged, with large nuclei and deep staining. After the intervention of the medicinal composition, the tumor cells are loosely arranged. After the intervention of the chondramus polysaccharide composition, the tumor cells show different degrees of damage and apoptosis, and after the intervention of the chondramus polysaccharide composition, the phenomenon of cell disintegration and structure disappearance occurs. Ki67 is a nuclear protein related to cell proliferation. Ki67 immunohistochemical staining analysis can be used to study the proliferation of tumor cells. The experimental results further show that the chondramus polysaccharide and its composition after intervention can reduce the expression of Ki67 protein in LLC mice, and the effect of chondramus polysaccharide composition is the best.

[0066] 3. Chondramus polysaccharide and chondramus polysaccharide composition protect immune organs

[0067] Thymus and spleen are the main organs for the maturation and differentiation of immune cells, and their organ indexes are basic indicators for measuring the immune function of the body.

[0068] Table 2 Effect of chondramus polysaccharide and its composition on immune organs of lung cancer mice

[0069]

[0070]

[0071] * p<0.05, ** p<0.01 and *** p<0.001 vs blank group; # p<0.05, ## p<0.01 and ### p<0.001 vs model group

[0072] Table 2 shows the changes of organ indexes of mice. Compared with the blank, the thymus index and spleen index of the model group increased significantly, indicating that the thymus and spleen of the tumor mice were negatively immunoregulated. After the intervention of each drug group, the immune organ enlargement caused by tumor growth was inhibited, and the organ index of lung cancer mice was obviously restored to normal level by chondramus polysaccharide composition. This means that chondramus polysaccharide combined with artemisia scoparia, eucommia ulmoides leaf and allium macrostemon enhances the effect of chondramus polysaccharide in relieving lung cancer, and plays a synergistic effect, and the effect can improve the immune function of the body.

[0073] 4. Chondramus polysaccharide and chondramus polysaccharide composition regulate cytokines in lung cancer mice

[0074] Inflammation aggravation is an important factor to promote tumor formation, and it is crucial to control inflammation to prevent tumor formation. In this experiment, the content of TNF-α, IL-1β and IL-6 in serum was detected by ELISA to evaluate the inflammation level of tumor mice.

[0075] Table 3 Effect of Radix Achyranthis Bidentata Polysaccharide and Its Composition on Inflammatory Factors of Lung Cancer Mice

[0076] Group Dose TNF-α (pg / mL) IL-1β (pg / mL) IL-6 (pg / mL) Blank group Saline 451.10±61.46 54.44±13.14 69.30±12.06 Model group Saline 603.62 ± 59.45 *** ]] 96.91 ± 10.74 *** ]] 100.02 ± 11.37 *** ]] Radix Achyranthis Bidentatae polysaccharide 150 mg / kg / d 492.59 ± 31.71 ## ]] 77.71 ± 7.47 # ]] 82.23 ± 9.69 ## ]] Medicinal material composition 150 mg / kg / d 535.54±55.89 86.34±18.65 83.65 ± 8.23 ## ]] Radix Achyranthis Bidentatae polysaccharide composition 150 mg / kg / d 472.48 ± 23.45 ### ]] 69.42 ± 14.31 ### ]] 73.93 ± 10.47 ### ]]

[0077] * p<0.05, ** p<0.01 and *** p<0.001 vs blank group; # p<0.05, ## p<0.01 and ### p<0.001 vs model group

[0078] Table 4 Effect of Radix Achyranthis Bidentata Polysaccharide and Its Composition on Growth Factors of Lung Cancer Mice

[0079] Group Dose VEGF (pg / mL) TGF-β (pg / mL) PDGF-BB (pg / mL) Blank group Saline 119.24±19.36 323.14±59.49 2566.59±296.044 Model group Saline 197.82 ± 19.94 *** ]] 641.23 ± 84.93 *** ]] 3525.56 ± 485.20 *** ]] Radix Achyranthis Bidentatae polysaccharide 150 mg / kg / d 167.48 ± 21.73 ## ]] 451.34 ± 34.56 ### ]] 2994.10 ± 205.50 # ]] Medicinal material composition 150 mg / kg / d 174.32 ± 24.58 # ]] 530.16 ± 53.21 # ]] 3274.50±312.19 Radix Achyranthis Bidentatae polysaccharide composition 150 mg / kg / d 159.48 ± 23.32 ## ]] 445.67 ± 59.64 ### ]] 2769.73 ± 365.45 ### ]]

[0080] * p<0.05, ** p<0.01 and *** p<0.001 vs blank group; # p<0.05, ## p<0.01 and ### p<0.001 vs model group

[0081] The results of inflammatory factors are shown in Table 3. Compared with the blank group, the contents of TNF-α, IL-1β and IL-6 in the model group were significantly increased, indicating that the immune function of tumor mice was affected and the release of pro-inflammatory factors was increased. After drug intervention, this phenomenon was obviously reversed, especially after the intervention of Radix Achyranthis Bidentata Polysaccharide composition. The experimental results showed that Radix Achyranthis Bidentata Polysaccharide could reduce the level of inflammatory factors, regulate the immune function of the body, inhibit the growth of tumor, and the combination of Radix Achyranthis Bidentata Polysaccharide, Eupatorium Fortunei, Eucommia Ulmoides Leaf and Allium Macrostemonum could play a greater effect. The expression of TNF-α, IL-1β and IL-6 in Radix Achyranthis Bidentata Polysaccharide composition group was reduced by 21.7%, 28.4% and 26.1% respectively, which was better than the regulation effect of Radix Achyranthis Bidentata Polysaccharide on inflammatory factors.

[0082] Tumor angiogenesis is a very important factor of tumor growth and metastasis, the present study by ELISA to investigate the serum VEGF, TGF-β and PDGF-BB levels, the results as shown in Table 4, the VEGF, TGF-β and PDGF-BB levels of the model group was significantly higher than the blank group, each drug group after intervention, the expression level of growth factors decreased significantly, wherein the chondrolic polysaccharide composition on VEGF, TGF-β and PDGF-BB expression was reduced by 19.4%, 30.5%, 21.4% compared with the model group, the effect was better than that of chondrolic polysaccharide on the regulation effect of growth factors, indicating that chondrolic polysaccharide composition can inhibit tumor angiogenesis and metastasis of lung cancer mice.

[0083] Although the present application has been disclosed with the preferred embodiments as above, it is not intended to limit the present application, and any person skilled in the art can make various modifications and modifications without departing from the spirit and scope of the present application, therefore the protection scope of the present application should be defined by the claims.

Claims

1. A Radix Achyranthis Bidentatae polysaccharide composition for intervening lung cancer, characterized in that, The chondrilla polysaccharide composition is: chondrilla polysaccharide 30-80 parts by mass, extract of rubus parvifolius 20-30 parts by mass, extract of eucommia ulmoides leaf 10-20 parts by mass, and extract of allium macrostemon Bunge 5-15 parts by mass; The preparation method of the extract of rubus parvifolius, the extract of eucommia ulmoides leaf, and the extract of allium macrostemon Bunge is as follows: According to the mass-volume ratio of rubus parvifolius, eucommia ulmoides leaf, and allium macrostemon Bunge to water being 1:(5-15), heating to 95-100 DEG C reflux extraction 1-3h, filtering, taking the first supernatant; The residue is extracted once according to the above process to obtain the second supernatant; Then the second and the second supernatant are combined, concentrated and freeze-dried into powder to obtain the extract of rubus parvifolius, the extract of eucommia ulmoides leaf, and the extract of allium macrostemon Bunge; The preparation method of the chondrilla polysaccharide is as follows: The chondrilla crude polysaccharide is obtained by soaking chondrilla sliced crude drug in water for 48-60h, the solid-liquid ratio being 1g:5-8mL, filtering the residue, adding acetone, standing for precipitation, dissolving the precipitate with water, dialysis for 60-72h, and freeze-drying; The chondrilla refined polysaccharide is obtained by dissolving the chondrilla crude polysaccharide in water, adding 6 times the volume of anhydrous ethanol, and separating the precipitate.

2. The use of the Achyranthes bidentata polysaccharide composition in the preparation of a drug for intervening in lung cancer, characterized in that, The chondrilla polysaccharide composition is: chondrilla polysaccharide 30-80 parts by mass, extract of rubus parvifolius 20-30 parts by mass, extract of eucommia ulmoides leaf 10-20 parts by mass, and extract of allium macrostemon Bunge 5-15 parts by mass; The preparation method of the extract of rubus parvifolius, the extract of eucommia ulmoides leaf, and the extract of allium macrostemon Bunge is as follows: According to the mass-volume ratio of rubus parvifolius, eucommia ulmoides leaf, and allium macrostemon Bunge to water being 1:(5-15), heating to 95-100 DEG C reflux extraction 1-3h, filtering, taking the first supernatant; The residue is extracted once according to the above process to obtain the second supernatant; Then the second and the second supernatant are combined, concentrated and freeze-dried into powder to obtain the extract of rubus parvifolius, the extract of eucommia ulmoides leaf, and the extract of allium macrostemon Bunge; The preparation method of the chondrilla polysaccharide is as follows: The chondrilla crude polysaccharide is obtained by soaking chondrilla sliced crude drug in water for 48-60h, the solid-liquid ratio being 1g:5-8mL, filtering the residue, adding acetone, standing for precipitation, dissolving the precipitate with water, dialysis for 60-72h, and freeze-drying; The chondrilla refined polysaccharide is obtained by dissolving the chondrilla crude polysaccharide in water, adding 6 times the volume of anhydrous ethanol, and separating the precipitate.

3. Use according to claim 2, characterized in that, The medicine comprises a pharmaceutically acceptable excipient.

4. Use according to claim 3, characterized in that, The excipient comprises one or more of lactose, maltose, microcrystalline cellulose, carboxymethyl cellulose, polyvinyl pyrrolidone, hydroxypropyl methyl cellulose, polymethyl methacrylate, starch, sucrose, glucose, aspartame, water, ethanol, glycerol, benzoic acid, formic acid, and sodium benzoate.

5. Use according to claim 2, characterized in that, The medicine is in any pharmaceutically acceptable dosage form.

6. Use according to claim 5, characterized in that, The dosage form comprises tablets, capsules, liquid preparations, injections, granules, tinctures, suppositories, patches, and inhalation preparations.

Images